FDA grants Priority Review to Gilotrif® for uncommon EGFR mutations in advanced NSCLC

Tuesday, October 10, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

- Submission is based on a meta-analysis of three LUX-Lung Phase III studies that examined Gilotrif® (afatinib) in NSCLC patients whose tumors have "uncommon" EGFR mutations: L861Q, G719X or S768I



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook